Bhatt Krushna, Roychoudhury Ajoy, Bhutia Ongkila, Trikha Anjan, Seith Ashu, Pandey Ravinder Mohan
Department of Oral and Maxillofacial Surgery, CDER, All India Institute of Medical Sciences, New Delhi, India.
J Oral Maxillofac Surg. 2010 Aug;68(8):1842-8. doi: 10.1016/j.joms.2009.09.005. Epub 2010 Jan 25.
The present study was undertaken to test bioresorbable fixation versus titanium for equivalence in terms of clinical union and complications using the American Association of Oral and Maxillofacial Surgeons parameters of care. The study design was a randomized, controlled, equivalence trial.
A total of 40 patients were enrolled and allocated to the titanium group and bioresorbable group using a computerized randomization table. All were plated using standard plating principles. In the bioresorbable group, 2 weeks of maxillomandibular fixation was also used. Evaluation of the study endpoint was done at 8 weeks postoperatively. For statistical analysis, the upper limit of the 95% confidence interval was calculated for failure to achieve the primary outcome variable and compared with the maximal clinically acceptable difference between the standard and test modalities in the failure to achieve clinical union (delta). Delta was predetermined as 2%. The other complications were tested for significance using Fisher's exact test.
Of the 40 patients, 21 were in the titanium group and 19 were in the bioresorbable group, with 20 men and 1 woman in the titanium group and 18 men and 1 woman in the bioresorbable group. The mean age was 28.7 years in the titanium group and 26.6 years in the bioresorbable group. In the titanium group, the complications noted were nonunion in 0%, malocclusion in 7.7%, continued postoperative swelling in 0%, chronic pain in 2%, infection in 5.2%, an inability to chew hard food after 8 weeks in 7.7%, the need for alternative treatment in 0%, and the need for reoperation in 31%. In the bioresorbable group, the complications were nonunion in 4.17%, malocclusion in 11.1%, swelling in 8.3%, chronic pain in 37.5%, infection in 0%, an inability to chew hard food in 11.1%, the need for alternative treatment in 11.1%, and need for reoperation for plate removal in 0%.
The small sample size did not allow any meaningful conclusion to be drawn from the present study in terms of the primary question of achieving union. Both groups matched in outcomes when evaluated only on a clinical basis. The avoidance of repeat surgery for plate removal is a definite advantage of using resorbable plates. However, the results are inconclusive in favor of any particular plating system.
本研究旨在根据美国口腔颌面外科医师协会的护理参数,测试生物可吸收固定与钛固定在临床愈合和并发症方面的等效性。研究设计为随机对照等效性试验。
共纳入40例患者,使用计算机随机化表将其分配至钛组和生物可吸收组。所有患者均采用标准的接骨板固定原则进行接骨板固定。在生物可吸收组中,还采用了2周的颌间固定。术后8周对研究终点进行评估。进行统计分析时,计算未达到主要结局变量的95%置信区间的上限,并与标准治疗方式和试验治疗方式在未实现临床愈合方面的最大临床可接受差异(δ)进行比较。δ预先设定为2%。使用Fisher精确检验对其他并发症进行显著性检验。
40例患者中,钛组21例,生物可吸收组19例,钛组有20名男性和1名女性,生物可吸收组有18名男性和1名女性。钛组的平均年龄为28.7岁,生物可吸收组为26.6岁。在钛组中,观察到的并发症有:骨不连发生率为0%,错牙合发生率为7.7%,术后持续肿胀发生率为0%,慢性疼痛发生率为2%,感染发生率为5.2%,8周后无法咀嚼硬食发生率为7.7%,需要替代治疗发生率为0%,需要再次手术发生率为31%。在生物可吸收组中,并发症有:骨不连发生率为4.17%,错牙合发生率为11.1%,肿胀发生率为8.3%,慢性疼痛发生率为37.5%,感染发生率为0%,无法咀嚼硬食发生率为11.1%,需要替代治疗发生率为11.1%,需要因取出接骨板而再次手术发生率为0%。
样本量较小,无法就实现骨愈合的主要问题从本研究中得出任何有意义的结论。仅在临床基础上评估时,两组的结果相当。避免因取出接骨板而再次手术是使用可吸收接骨板的一个明显优势。然而,结果尚无定论,无法支持任何一种特定的接骨板系统。